Skip to main content

Featured

North Korean Engineers Aid Russia in Kursk Mine-Clearing Operations

                               North Korea last year sent some 14,000 soldiers to fight alongside Russia in Kursk. Russia has announced that North Korean troops are playing a central role in de-mining operations in the Kursk region , an area heavily affected by months of fighting with Ukrainian forces. According to the Russian Defence Ministry, the deployment follows a mutual defence pact signed between Moscow and Pyongyang, which saw thousands of North Korean soldiers sent to assist Russia during the conflict. The Kursk region became a major battleground in August 2024, when Ukrainian forces crossed the border and seized large swathes of territory. After months of intense combat, Russian forces—bolstered by North Korean troops—eventually regained control. Now, the focus has shifted to clearing anti-tank mines, anti-personnel devices, and unexploded ordnance , including Western-supplied weapons...
Post a Comment
Read more

article

Labels

Alzheimer’s Drug Donanemab Receives FDA Advisers’ Endorsement for Slowing Disease Progression

 

A significant milestone has been reached in the fight against Alzheimer’s disease. Eli Lilly’s closely watched Alzheimer’s drug, donanemab, has won the unanimous backing of federal health advisers. The drug is specifically intended for people with mild dementia caused by this brain-robbing disease.

The decision by the Food and Drug Administration (FDA) advisers comes after careful consideration of the drug’s benefits and risks. Donanemab has demonstrated the ability to modestly slow cognitive decline and memory problems associated with Alzheimer’s. Although it’s not a cure, this endorsement represents a promising step forward in managing the disease.

Here are the key points:

  1. Effectiveness: Donanemab has shown effectiveness in slowing cognitive decline. Patients who received monthly intravenous infusions of the drug declined about 35% more slowly than those who received a placebo.
  2. Risk Assessment: The FDA panel weighed the risks, including side effects like brain swelling and bleeding, which will need monitoring. Despite these risks, the panel concluded that the drug’s benefits outweighed them.
  3. Tau Protein Screening: Unlike previous concerns about tau protein screening, most panelists believed there was enough evidence to prescribe the drug broadly without requiring such screening.
  4. FDA Decision: The FDA will make the final decision on approval later this year. If approved, donanemab would become only the second Alzheimer’s drug in the U.S. shown to convincingly slow cognitive decline.

This endorsement brings hope to individuals and families affected by Alzheimer’s, and we eagerly await the FDA’s final decision. Stay tuned for further updates on this groundbreaking development! 

Labels:

Comments

Post a Comment